CD47 and neoplasm: Additionally, systemic tumour-antigen-specific immune responses are stimulated by a nanobody antagonist of CD47 (CD47nb)-expressing bacteria, which inhibits the growth of untreated tumours and provides evidence of the abscopal effect of engineered bacterial immunotherapy (Chowdhury et al., 2019).